Skip to main content

Table 2 Echocardiographic parameters

From: Triptolide improves systolic function and myocardial energy metabolism of diabetic cardiomyopathy in streptozotocin-induced diabetic rats

 

Control

TP

DM

DM + TP, L

DM + TP, M

DM + TP, H

LVEDD, mm

6.4 ± 0.6

6.5 ± 0.7

5.9 ± 0.5

6.0 ± 0.6

5.6 ± 0.6

5.4 ± 0.8

LVEDD index, um/g

13.8 ± 1.6

13.7 ± 2.1

23.6 ± 3.0*

21.1 ± 1.9*

20.2 ± 1.5*#

19.0 ± 1.8*#

LVESD, mm

3.9 ± 0.4

3.8 ± 0.7

3.7 ± 0.6

3.8 ± 0.8

3.3 ± 0.5

3.2 ± 0.8

LVESD index, um/g

8.4 ± 0.8

8.3 ± 0.7

15.8 ± 1.9*

13.5 ± 1.7*

12.9 ± 1.3*#

12.5 ± 1.6*#

LVEF,%

76.4 ± 8.2

78.2 ± 6.3

66.6 ± 6.5*

72.8 ± 5.5

75.0 ± 5.8#

74.6 ± 6.4#

FS,%

44.7 ± 4.3

43.7 ± 5.1

35.8 ± 3.6*

38.9 ± 4.1

41.3 ± 4.9

42.4 ± 4.6

  1. LVEDD left ventricular end-diastolic dimension, LVESD left ventricular end-systolic dimension, LVEF left ventricular ejection fraction, FS fractional shortening. TP,L low-dose triptolide (100 μg/kg/day), TP, M medium-dose triptolide (200 μg/kg/day); TP, H high-dose triptolide (400 μg/kg/day). *P < 0.05 versus Control; #P < 0.05versus DM